US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS

230.98

+2.841.24%

Post-market: 229.75-1.0150-0.44%17:21 EDT

Volume:519.87K

Turnover:119.89M

Market Cap:24.88B

PE:-37.72

High:234.15

Open:229.30

Low:227.40

Close:228.14

Loading ...

Overview Company News Filings

BeiGene (ONC) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Sector Update: Health Care Stocks Decline Premarket Thursday

MT Newswires Live

Stock Track | BeiGene Soars Over 5% as Q4 Results Beat Estimates, Upbeat 2025 Outlook

Beigene Ltd reports results for the quarter ended September 30 - Earnings Summary

BeiGene Ltd BeiGene Q4 Net Loss Narrows, Revenue Rises; 2025 Revenue Guidance Set

MT Newswires Live

BeiGene Expects 2025 Total Revenue Of $4.9B-$5.3B Versus $3.81B YoY

BeiGene Q4 2024 GAAP EPADS $(1.43) Up From $(3.53) YoY, Sales $1.13B Versus $634.41M YoY

BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

BeiGene to Present at Upcoming Investor Conferences

Beigene Ltd expected to post a loss of 89 cents a share - Earnings Preview

US Stocks Trading Below Estimated Value In February 2025

Simply Wall St.

BeiGene (ONC) Soars 3.2%: Is Further Upside Left in the Stock?

Nomura Adjusts BeiGene Price Target to $316.65 From $293.78, Maintains Buy Rating

MT Newswires Live

HRMY or ONC: Which Is the Better Value Stock Right Now?

Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:ONC) 41% Undervaluation?

Simply Wall St.

BeiGene, Ltd. (NASDAQ:ONC) Stock Catapults 26% Though Its Price And Business Still Lag The Industry

Simply Wall St.

ImmunityBio Shares Rise After Collaboration, Supply Agreement With BeiGene

Exploring High Growth Tech Stocks in January 2025

Simply Wall St.

When Can We Expect A Profit From BeiGene, Ltd. (NASDAQ:ONC)?

Simply Wall St.

BeiGene (ONC) Moves 8.9% Higher: Will This Strength Last?

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ONC/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS","latestPrice":230.98,"timestamp":1744920000000,"preClose":228.14,"halted":0,"volume":519865,"hourTrading":{"tag":"盘后","latestPrice":229.75,"preClose":230.765,"latestTime":"17:21 EDT","volume":54100,"amount":12495855.13,"timestamp":1744924915084},"delay":0,"floatShares":79387510,"shares":107719405,"eps":-6.124009,"marketStatus":"Closed Good Friday","change":2.84,"latestTime":"04-17 16:00:00 EDT","open":229.3,"high":234.15,"low":227.3961,"amount":119885584.17555,"amplitude":0.029604,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-6.124009,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":228.14,"preHourTrading":{"tag":"盘前","latestPrice":233.81,"preClose":228.14,"latestTime":"08:41 EDT","volume":73,"amount":17065.739250000002,"timestamp":1744893686762},"postHourTrading":{"tag":"盘后","latestPrice":229.75,"preClose":230.765,"latestTime":"17:21 EDT","volume":54100,"amount":12495855.13,"timestamp":1744924915084},"volumeRatio":0.7116059393545304,"impliedVol":0.529,"impliedVolPercentile":0.8767},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":79387510,"roa":"-6.07%","roe":"-18.77%","lyrEps":-6.124009,"volumeRatio":0.7116059393545304,"shares":107719405,"dividePrice":0,"high":234.15,"amplitude":0.029604,"preClose":228.14,"low":227.3961,"week52Low":126.9681,"pbRate":"7.47","psRate":"6.53","week52High":287.88,"institutionHeld":0,"latestPrice":230.98,"eps":-6.124009,"divideRate":0,"volume":519865,"delay":0,"ttmEps":-6.124009,"open":229.3,"prevYearClose":184.71,"prevWeekClose":230.36,"prevMonthClose":272.17,"prevQuarterClose":272.17,"fiveDayClose":208.31,"twentyDayClose":262.59,"sixtyDayClose":222.22,"earningDate":1746547200000,"earningTime":"盘前"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514382089","title":"BeiGene (ONC) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2514382089","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514382089?lang=en_us&edition=fundamental","pubTime":"2025-02-27 22:30","pubTimestamp":1740666627,"startTime":"0","endTime":"0","summary":"For the quarter ended December 2024, BeiGene, Ltd.  reported revenue of $1.13 billion, up 77.8% over the same period last year. EPS came in at -$1.43, compared to -$3.53 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $1.09 billion, representing a surprise of +3.76%. The company delivered an EPS surprise of -62.50%, with the consensus EPS estimate being -$0.88.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Product revenue, net: $1.12 billion versus $1.08 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +77.3% ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beigene-onc-q4-earnings-taking-143027178.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ONC"],"gpt_icon":0},{"id":"2514004388","title":"Sector Update: Health Care Stocks Decline Premarket Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=2514004388","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514004388?lang=en_us&edition=fundamental","pubTime":"2025-02-27 22:22","pubTimestamp":1740666144,"startTime":"0","endTime":"0","summary":"Health care stocks declined premarket Thursday as the Health Care Select Sector SPDR Fund (XLV) was 0.2% lower and the iShares Biotechnology ETF (IBB) was down 0.8% recently.Viatris (VTRS) shares fell","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4583","XLV","VTRS","BK4196","BK4581","BK4007","IBB","LU1839511570.USD","BK4535","ONC","LU2087621335.USD","BK4539","BK4139","LFST","BK4585"],"gpt_icon":0},{"id":"1191662413","title":"Stock Track | BeiGene Soars Over 5% as Q4 Results Beat Estimates, Upbeat 2025 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=1191662413","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191662413?lang=en_us&edition=fundamental","pubTime":"2025-02-27 21:02","pubTimestamp":1740661360,"startTime":"0","endTime":"0","summary":"BeiGene Ltd  stock soared 5.79% in pre-market trading on Thursday, February 27, 2025, following the company's strong financial results for the fourth quarter and full year 2024, coupled with an upbeat revenue guidance for 2025.The global oncology company reported better-than-expected revenue for Q4 2024, driven by robust sales growth of its flagship product BRUKINSA. Total revenue for the quarter stood at $1.13 billion, a 78% increase from the year-ago period, surpassing analyst estimates of $1.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ONC"],"gpt_icon":0},{"id":"2514064058","title":"Beigene Ltd reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2514064058","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514064058?lang=en_us&edition=fundamental","pubTime":"2025-02-27 20:27","pubTimestamp":1740659239,"startTime":"0","endTime":"0","summary":"Beigene Ltd reports results for the quarter ended September 30 - Earnings SummaryBeigene Ltd ONC.OQ reported a quarterly adjusted loss of $1.87 per share for the quarter ended September 30, higher tha","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nL5N3PI1EI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC","688235"],"gpt_icon":0},{"id":"2514391808","title":"BeiGene Ltd BeiGene Q4 Net Loss Narrows, Revenue Rises; 2025 Revenue Guidance Set","url":"https://stock-news.laohu8.com/highlight/detail?id=2514391808","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514391808?lang=en_us&edition=fundamental","pubTime":"2025-02-27 19:33","pubTimestamp":1740656003,"startTime":"0","endTime":"0","summary":"BeiGene Ltd  reported a Q4 net loss Thursday of $1.43 per American depositary share, narrowing from $3.53 per share a year earlier.Analysts polled by FactSet expected a loss of $1.01.Revenue for the quarter ended Dec. 31 was $1.13 billion, up from $634.4 million a year earlier.Analysts surveyed by FactSet expected $1.04 billion.The company expects full year revenue between $4.9 billion and $5.3 billion.Analysts polled by FactSet expect $4.73 billion.BeiGene shares were up more than 3% in recent Thursday premarket activity.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06160","ONC"],"gpt_icon":0},{"id":"2514870960","title":"BeiGene Expects 2025 Total Revenue Of $4.9B-$5.3B Versus $3.81B YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2514870960","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514870960?lang=en_us&edition=fundamental","pubTime":"2025-02-27 19:10","pubTimestamp":1740654614,"startTime":"0","endTime":"0","summary":"Full Year 2025 GuidanceBeiGene&#39;s financial guidance is summarized below:  FY 20251Total Revenue $4.9 billion to $5.3 billionGAAP Operating Expenses (R&amp;D and SG&amp;A) $4.1 billion to $4.4","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/general/biotech/25/02/44000994/beigene-expects-2025-total-revenue-of-4-9b-5-3b-versus-3-81b-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSS","06160","ONC"],"gpt_icon":0},{"id":"2514877685","title":"BeiGene Q4 2024 GAAP EPADS $(1.43) Up From $(3.53) YoY, Sales $1.13B Versus $634.41M YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2514877685","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514877685?lang=en_us&edition=fundamental","pubTime":"2025-02-27 19:04","pubTimestamp":1740654262,"startTime":"0","endTime":"0","summary":"BeiGene (NASDAQ:ONC) reported quarterly losses of $(1.43) per share. This is a 59.49 percent increase over losses of $(3.53) per share from the same period last year.  The company reported quarterly sales of $1.13","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/02/44000920/beigene-q4-2024-gaap-epads-1-43-up-from-3-53-yoy-sales-1-13b-versus-634-41m-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BeiGene Q4 2024 GAAP EPADS $(1.43) Up From $(3.53) YoY, Sales $1.13B Versus $634.41M YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160","ONC"],"gpt_icon":0},{"id":"2514877680","title":"BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2514877680","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514877680?lang=en_us&edition=fundamental","pubTime":"2025-02-27 19:00","pubTimestamp":1740654000,"startTime":"0","endTime":"0","summary":"Total global revenues of $1.1 billion and $3.8 billion for the fourth quarter and full year, increases of 78% and 55%, respectively; narrowed GAAP operating loss and achieved full-year positive non-GAAP operating income. Global BRUKINSA revenues of $828 million and $2.6 billion for the fourth quarter and full year, increases of 100% and 105%, respectively; progressed pivotal-stage programs for BCL2 inhibitor sonrotoclax and BTK CDAC BGB-16673. Advanced six and 13 New Molecular Entities  into the clinic in the fourth quarter and full year, respectively; anticipate multiple data readouts for innovative solid tumor programs in 1H 2025. Full year 2025 revenue guidance of $4.9 billion to $5.3 billion, reaffirm anticipated positive GAAP operating income and cash flow generation from operations in 2025","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beigene-announces-fourth-quarter-full-110000380.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4201","BK4139","LU2463526074.USD","ASH","BK4107","LU0053666078.USD","L","BK4585","ONC","BK4109","BK4588","EC"],"gpt_icon":0},{"id":"2514062583","title":"BeiGene to Present at Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2514062583","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514062583?lang=en_us&edition=fundamental","pubTime":"2025-02-25 19:01","pubTimestamp":1740481260,"startTime":"0","endTime":"0","summary":"SAN MATEO, Calif., February 25, 2025----BeiGene, Ltd. , a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the Company will participate in fireside chats at two upcoming investor conferences:. TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:10 am ET; and. Leerink Partners Global Biopharma Conference on Monday, March 10, 2025 at 1:00 pm ET. These presentations may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeiGene's plans, commitments, aspirations and goals related to BeiGene’s medicines and drug candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors which are discussed in the section entitled \"Risk Factors\" in BeiGene’s most recent periodic report filed with the U.S. Securities and Exchang","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beigene-present-upcoming-investor-conferences-110100748.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ONC","BK4139"],"gpt_icon":0},{"id":"2514805130","title":"Beigene Ltd  expected to post a loss of 89 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2514805130","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514805130?lang=en_us&edition=fundamental","pubTime":"2025-02-25 16:02","pubTimestamp":1740470565,"startTime":"0","endTime":"0","summary":"Beigene Ltd  expected to post a loss of89cents a share - Earnings Preview Beigene Ltd ONC.OQ, ONC.O is expected to show a rise in quarterly revenue when it reports  results on February 27 for the peri","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nL5N3PG0HQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC","688235"],"gpt_icon":0},{"id":"2513502772","title":"US Stocks Trading Below Estimated Value In February 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2513502772","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513502772?lang=en_us&edition=fundamental","pubTime":"2025-02-21 18:02","pubTimestamp":1740132137,"startTime":"0","endTime":"0","summary":"As of February 2025, the U.S. stock market has experienced a mixed performance with recent declines following record highs for major indices like the S&P 500. This fluctuation presents an opportunity to explore stocks that may be trading below their estimated value, particularly in a market environment where identifying companies with strong fundamentals and potential for growth can be key to making informed investment decisions.Top 10 Undervalued Stocks Based On Cash Flows In The United States. Overview: BeiGene, Ltd. is an oncology company focused on discovering and developing cancer treatments globally, with a market cap of approximately $25.26 billion.BeiGene, soon to be BeOne Medicines Ltd., is trading at US$244.20, significantly below its estimated fair value of US$377.86, highlighting its undervaluation based on cash flows. The company anticipates profitability within three years and forecasts a 66.96% annual earnings growth r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/us-stocks-trading-below-estimated-100217863.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["LU0957808578.USD","LU1366333091.USD","LU1852331112.SGD","LU1934455277.USD","LU0205194284.USD","LU0965509101.SGD","LU0208291251.USD","LU0719512351.SGD","LU1429558221.USD","LU1934455863.HKD","LU2054465674.USD","LU1037948541.HKD","IE0004445239.USD","LU0205193047.USD","LU1169589451.USD","ORCL","IE00BMPRXN33.USD","LU1642822529.SGD","LU0234570918.USD","LU1989764664.SGD","ONC","BK7078","LNW","SEI","LU0082616367.USD","IE00B5949003.HKD","IE00B7SZL793.SGD","LNW.AU","LU0738911758.USD","LU0444971666.USD","LU0289960550.SGD","LU0861579265.USD","LU0965509283.SGD","LU0012050646.USD","LU1489326972.SGD","LU0949170772.SGD","LU0106261612.USD","BK4538","BK4588","LU1935042215.USD","LU0889565833.HKD","HAE","LU1935043536.SGD","LU0661504455.SGD","IE00BN8TJ469.HKD","LU1803068979.SGD","LU0130102774.USD","LU0256863811.USD","LU2108987350.USD","LU0198837287.USD","LU1506573853.SGD","BK4179"],"gpt_icon":1},{"id":"2513250080","title":"BeiGene (ONC) Soars 3.2%: Is Further Upside Left in the Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2513250080","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513250080?lang=en_us&edition=fundamental","pubTime":"2025-02-21 16:24","pubTimestamp":1740126240,"startTime":"0","endTime":"0","summary":"BeiGene, Ltd.  shares ended the last trading session 3.2% higher at $244.20. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 6.5% gain over the past four weeks.The stock price rally can be attributed to positive investor mindset regarding the sales growth potential of its internally discovered oncology products, including Brukinsa  and Tevimbra . BeiGene has several other pipeline candidates that are being developed for treating various cancer indications.This company is expected to post quarterly loss of $0.80 per share in its upcoming report, which represents a year-over-year change of +77.3%. Revenues are expected to be $1.09 billion, up 71.5% from the year-ago quarter.Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beigene-onc-soars-3-2-082400824.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ONC","APLT","LU0320765992.SGD","BK4139","LU0109394709.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2512159913","title":"Nomura Adjusts BeiGene Price Target to $316.65 From $293.78, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2512159913","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512159913?lang=en_us&edition=fundamental","pubTime":"2025-02-18 20:09","pubTimestamp":1739880586,"startTime":"0","endTime":"0","summary":"Nomura Adjusts BeiGene Price Target to $316.65 From $293.78, Maintains Buy Rating","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ONC","NMR","06160"],"gpt_icon":0},{"id":"2512992203","title":"HRMY or ONC: Which Is the Better Value Stock Right Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2512992203","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512992203?lang=en_us&edition=fundamental","pubTime":"2025-02-18 00:40","pubTimestamp":1739810413,"startTime":"0","endTime":"0","summary":"Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc.  and BeiGene, Ltd. . But which of these two stocks is more attractive to value investors?We'll need to take a closer look to find out.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.Harmony Biosciences Holdings, Inc. has a Zacks Rank of #1 , while BeiGene, Ltd. has a Zacks Rank of #3  right now. Investors should feel comfortable knowing that HRMY likely has seen a stronger improvement to its earnings outlook than ONC has recently. But this is only part of the picture for value investors.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hrmy-onc-better-value-stock-164013176.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ONC","BK4139","HRMY","BK4007"],"gpt_icon":0},{"id":"2511003733","title":"Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:ONC) 41% Undervaluation?","url":"https://stock-news.laohu8.com/highlight/detail?id=2511003733","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511003733?lang=en_us&edition=fundamental","pubTime":"2025-02-13 00:59","pubTimestamp":1739379568,"startTime":"0","endTime":"0","summary":"The projected fair value for BeiGene is US$376 based on 2 Stage Free Cash Flow to Equity. BeiGene is estimated to be 41% undervalued based on current share price of US$221. The CN283 analyst price target for ONC is 25% less than our estimate of fair value. Today we will run through one way of estimating the intrinsic value of BeiGene, Ltd.  by projecting its future cash flows and then discounting them to today's value. We will use the Discounted Cash Flow  model on this occasion. Models like these may appear beyond the comprehension of a lay person, but they're fairly easy to follow.Terminal Value = FCF2034 ×  ÷  =","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/opportunity-beigene-ltd-nasdaq-onc-165928612.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BGHQF748.EUR","BK4139",".IXIC","QLD","SQQQ","IE00BKPKM429.USD","NQmain","PSQ","LU2210150020.SGD","BK4211","TQQQ","IE00B3QW5Z07.USD","LU2095319765.USD","MNQmain","LU2210149790.SGD","DCF","TSYW.SI","BK4588","NDAQ","TV","BEIGF","BK4585","QID","IE00B64PRP62.GBP","BK4112","USAW.SI","BK4100","NVIW.SI","ONC","FCF","USJW.SI"],"gpt_icon":1},{"id":"2509278518","title":"BeiGene, Ltd. (NASDAQ:ONC) Stock Catapults 26% Though Its Price And Business Still Lag The Industry","url":"https://stock-news.laohu8.com/highlight/detail?id=2509278518","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509278518?lang=en_us&edition=fundamental","pubTime":"2025-02-06 18:15","pubTimestamp":1738836906,"startTime":"0","endTime":"0","summary":"BeiGene, Ltd. ( NASDAQ:ONC ) shares have had a really impressive month, gaining 26% after a shaky period beforehand...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beigene/news/beigene-ltd-nasdaqonc-stock-catapults-26-though-its-price-an","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1500","IE00B64PRP62.GBP","IE00BGHQF748.EUR","TSYW.SI","QID","IE00B3QW5Z07.USD","NQmain","BK1588","BK4112","USJW.SI","BK1583","LU2210150020.SGD","MNQmain","LU0307460666.USD","NVIW.SI","PSQ","LU0588546209.SGD","LU2210149790.SGD",".IXIC","IE00BKPKM429.USD","ONC","SQQQ","BK4588","TQQQ","LU2328871848.SGD","BK1161","06160","BK4139","USAW.SI","BK4585","LU2095319765.USD","QLD","BEIGF","LU1969619763.USD","NDAQ"],"gpt_icon":1},{"id":"2507163016","title":"ImmunityBio Shares Rise After Collaboration, Supply Agreement With BeiGene","url":"https://stock-news.laohu8.com/highlight/detail?id=2507163016","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507163016?lang=en_us&edition=fundamental","pubTime":"2025-01-29 23:44","pubTimestamp":1738165440,"startTime":"0","endTime":"0","summary":"ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene.The two companies will conduct a confirmatory randomized Phase 3 clinical trial, combining BeiGene's tislelizumab and ImmunityBio's Anktiva.The Phase 3 study aims to confirm the efficacy and safety of the combination, and provide evidence of the potential for these two immunotherapeutic agents to improve overall survival in patients with advanced or metastatic non-small cell lung cancer who have acquired resistance to immune checkpoint inhibitor therapy.Immunity Bio said that multiple Phase 1 and 2 studies have demonstrated prolonged overall survival with this combination approach, in comparison to historical results with chemotherapy in this patient population.ImmunityBio will conduct this confirmatory Phase 3 trial globally across multiple sites. When fully enrolled, it is expected to include 462 participants.The primary endpoint of the study is overall survival, w","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0588546209.SGD","LU1969619763.USD","06160","IBRX","BK1500","BK4139","ONC","LU0307460666.USD","BK1161","BK1583","LU2328871848.SGD","BK1588"],"gpt_icon":0},{"id":"2505972300","title":"Exploring High Growth Tech Stocks in January 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2505972300","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505972300?lang=en_us&edition=fundamental","pubTime":"2025-01-22 22:02","pubTimestamp":1737554568,"startTime":"0","endTime":"0","summary":"The United States market has experienced a notable upswing, climbing by 3.8% over the past week and achieving a 24% increase over the last year, with earnings forecasted to grow by 15% annually. In this favorable environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and robust financial health to capitalize on these positive market trends.Top 10 High Growth Tech Companies In The United States. Gilead Sciences, a biopharmaceutical firm, is intensifying its strategic focus through recent alliances and acquisition pursuits. With an annualized revenue growth of 2.8% and earnings expansion at 31.1%, the company's commitment to innovation is underscored by substantial R&D investments, totaling $5 billion last year alone—equating to about 20% of its revenue. Recent strategic moves include a partnership with LEO Pharma to develop treatments for inflammatory diseases and acquiring options for novel therapies from Terray Ther","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exploring-high-growth-tech-stocks-140248889.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2087621335.USD","IE00B7SZLL34.SGD","LU0058720904.USD","LU0348723411.USD","BK4139","IE00B19Z3B42.SGD","BK4550","BK4588","IE00BZ1G4Q59.USD","BK4578","GILD","LU0320765992.SGD","LU1585245621.USD","BK4585","BK4568","BK4583","LU0234570918.USD","LU1066053197.SGD","LU1430594728.SGD","ONC","LU1066051498.USD","LU1169589451.USD","IE00BKVL7J92.USD","LU0109394709.USD","IE00B3T34201.USD","IE00BSNM7G36.USD","LU1839511570.USD","BK4532","DT","BK4566","BK4023","LU1169590202.USD","BK4560","LU0289739699.SGD","LU1571399168.USD","IE00B19Z3581.USD","LU2468319806.SGD","LU0889565916.HKD","IE0002270589.USD"],"gpt_icon":0},{"id":"2504816289","title":"When Can We Expect A Profit From BeiGene, Ltd. (NASDAQ:ONC)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2504816289","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504816289?lang=en_us&edition=fundamental","pubTime":"2025-01-20 22:28","pubTimestamp":1737383337,"startTime":"0","endTime":"0","summary":"With the business potentially at an important milestone, we thought we'd take a closer look at BeiGene, Ltd.'s  future prospects. BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. With the latest financial year loss of CN6.3b and a trailing-twelve-month loss of CN6.0b, the US$22b market-cap company alleviated its loss by moving closer towards its target of breakeven. The most pressing concern for investors is BeiGene's path to profitability – when will it breakeven?Below we will provide a high-level summary of the industry analysts’ expectations for the company.Consensus from 31 of the American Biotechs analysts is that BeiGene is on the verge of breakeven. They expect the company to post a final loss in 2025, before turning a profit of CN2.8b in 2026. The company is therefore projected to breakeven just over a year from now. What rate will the company have to grow y","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/expect-profit-beigene-ltd-nasdaq-142857944.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2210149790.SGD","BK4139","SQQQ","NDAQ",".IXIC","TQQQ","BK4588","QID","BK4585","USAW.SI","IE00B64PRP62.GBP","NVIW.SI","USJW.SI","QLD","MNQmain","IE00BKPKM429.USD","TSYW.SI","ONC","LU2095319765.USD","PSQ","BEIGF","NQmain","LU2210150020.SGD","BK4112","IE00BGHQF748.EUR","IE00B3QW5Z07.USD"],"gpt_icon":1},{"id":"2503646626","title":"BeiGene (ONC) Moves 8.9% Higher: Will This Strength Last?","url":"https://stock-news.laohu8.com/highlight/detail?id=2503646626","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503646626?lang=en_us&edition=fundamental","pubTime":"2025-01-15 21:57","pubTimestamp":1736949420,"startTime":"0","endTime":"0","summary":"BeiGene, Ltd.  shares rallied 8.9% in the last trading session to close at $200.99. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 4.7% gain over the past four weeks.The stock rallied as optimism grew over the company’s internally discovered oncology products, including Brukinsa  and Tevimbra  and other pipeline candidates that are being developed for treating various cancer indications.This company is expected to post quarterly loss of $0.71 per share in its upcoming report, which represents a year-over-year change of +79.9%. Revenues are expected to be $1.09 billion, up 72.2% from the year-ago quarter.Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.BeiGene is part of the Zacks Medical - Biomedica","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beigene-onc-moves-8-9-135700473.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2125909593.SGD","ONC","BK4121","LU2433249047.HKD","BK4139","LU1923622614.USD","LU2125909247.SGD","QGEN"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":62,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"date":"2025-05-07","symbol":"ONC","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":-0.74,"defaultRemindTime":1746604800000,"name":null,"time":"Pre-Market","dateTimestamp":1746590400000,"actualEps":null},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43},{"market":"US","date":"2024-11-12","symbol":"ONC","fiscalQuarterEnding":"2024/09","expectedEps":-0.88,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-08-07","symbol":"ONC","fiscalQuarterEnding":"2024/06","expectedEps":-2.1,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-05-11","symbol":"ONC","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715400000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2727,"buy":0.6818,"hold":0.0455,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6818,"analysts":22,"updateTime":1744084800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2025-04-17","current":-38.113584,"percent":0.422535,"low":-46.072488,"twenty":-42.748137,"median":-33.549429,"eighty":-28.784295,"high":-22.805663,"avg":-34.842528,"sd":7.324243,"marketCap":24575105056},"quantilePoints":[{"date":"2025-01-03","current":-23.85925,"twenty":-23.85925,"median":-23.85925,"eighty":-23.85925,"marketCap":19590153584},{"date":"2025-01-10","current":-23.169003,"twenty":-23.588216,"median":-23.51181,"eighty":-23.096335,"marketCap":18938568040},{"date":"2025-01-17","current":-26.770744,"twenty":-26.217794,"median":-23.689854,"eighty":-23.142836,"marketCap":21882666138},{"date":"2025-01-24","current":-28.798988,"twenty":-27.60701,"median":-25.13119,"eighty":-23.374687,"marketCap":23683664763},{"date":"2025-01-31","current":-29.253094,"twenty":-28.895055,"median":-26.770744,"eighty":-23.516999,"marketCap":24179205805},{"date":"2025-02-07","current":-29.699946,"twenty":-29.114029,"median":-28.456686,"eighty":-23.723733,"marketCap":24422582437},{"date":"2025-02-14","current":-29.279798,"twenty":-29.132261,"median":-28.781271,"eighty":-23.9826,"marketCap":24061904635},{"date":"2025-02-21","current":-31.546239,"twenty":-29.269116,"median":-28.798062,"eighty":-24.917918,"marketCap":26058437677},{"date":"2025-02-28","current":-46.072488,"twenty":-30.312806,"median":-28.916244,"eighty":-26.238043,"marketCap":29706894943},{"date":"2025-03-07","current":-42.702936,"twenty":-33.205878,"median":-29.060335,"eighty":-26.487572,"marketCap":27534255325},{"date":"2025-03-14","current":-42.304107,"twenty":-40.627279,"median":-29.228112,"eighty":-26.926934,"marketCap":27277096074},{"date":"2025-03-21","current":-43.63686,"twenty":-41.989697,"median":-29.279798,"eighty":-27.60701,"marketCap":28136436571},{"date":"2025-03-28","current":-43.795471,"twenty":-42.273573,"median":-29.808923,"eighty":-28.393975,"marketCap":28238706493},{"date":"2025-04-04","current":-44.082326,"twenty":-43.290212,"median":-30.877376,"eighty":-28.597906,"marketCap":28423666794},{"date":"2025-04-11","current":-34.741183,"twenty":-42.946887,"median":-33.164233,"eighty":-28.695114,"marketCap":22400628140},{"date":"2025-04-17","current":-38.113584,"twenty":-42.748137,"median":-33.549429,"eighty":-28.784295,"marketCap":24575105056}],"updateTime":1745032417555}}}